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ABSTRACT
Objective TgF-β2 (TgF-β, transforming growth 
factor beta), the less- investigated sibling of TgF-β1, 
is deregulated in rodent and human liver diseases. 
Former data from bile duct ligated and MDr2 knockout 
(KO) mouse models for human cholestatic liver disease 
suggested an involvement of TgF-β2 in biliary- derived 
liver diseases.
Design as we also found upregulated TGFB2 in liver 
tissue of patients with primary sclerosing cholangitis 
(Psc) and primary biliary cholangitis (PBc), we now 
fathomed the positive prospects of targeting TgF-β2 
in early stage biliary liver disease using the MDr2- KO 
mice. specifically, the influence of TgfB2 silencing on 
the fibrotic and inflammatory niche was analysed on 
molecular, cellular and tissue levels.
Results TgfB2- induced expression of fibrotic genes in 
cholangiocytes and hepatic stellate cellswas detected. 
TgfB2 expression in MDr2- KO mice was blunted using 
TgfB2- directed antisense oligonucleotides (aOn). 
Upon aOn treatment, reduced collagen deposition, 
hydroxyproline content and αsMa expression as well 
as induced PparG expression reflected a significant 
reduction of fibrogenesis without adverse effects 
on healthy livers. expression analyses of fibrotic and 
inflammatory genes revealed aOn- specific regulatory 
effects on Ccl3, Ccl4, Ccl5, Mki67 and Notch3 
expression. Further, aOn treatment of MDr2- KO mice 
increased tissue infiltration by F4/80- positive cells 
including eosinophils, whereas the number of cD45- 
positive inflammatory cells decreased. in line, TGFB2 
and cD45 expression correlated positively in Psc/PBc 
patients and localised in similar areas of the diseased 
liver tissue.
Conclusions Taken together, our data suggest a new 
mechanistic explanation for amelioration of fibrogenesis 
by TgF-β2 silencing and provide a direct rationale for 
TgF-β2- directed drug development.
InTRODuCTIOn
Primary sclerosing cholangitis (PSC) and primary 
biliary cholangitis (PBC) are rare chronic auto-
immune liver diseases, which are initiated by 
inflammatory attacks towards the biliary system.1 
Parenchymal damage, unresolved inflamma-
tion, compensatory hepatocyte proliferation and 
matrix deposition by hepatic stellate cells (HSCs) 
and portal myofibroblasts lead to fibrosis and 
subsequent cirrhosis.2 Of note, 15%–25% of PBC 
Significance of this study
What is already known on this subject?
 ► Chronic liver diseases (CLDs) are a major 
global health issue developing from fibrosis, 
via cirrhosis to hepatocellular carcinoma, the 
second deadliest cancer worldwide.
 ► Fibrotic rearrangements are reversible and thus 
offer a well- druggable disease stage.
 ► We recently described isoform TGF-β2 (TGF-β, 
transforming growth factor beta) to be 
deregulated in human and rodent CLDs with a 
probably special impact in biliary- derived CLDs.
What are the new findings?
 ► We here describe for the first time the 
antifibrotic and immune- regulative prospects of 
TgfB2 silencing in multidrug resistance gene 2 
knockout (MDR2- KO) mice.
 ► TgfB2- specific antisense oligonucleotides 
(AONs) target liver sinusoidal endothelial 
cells as well as activated fibroblasts and 
macrophages.
 ► TgfB2 silencing by AONs specifically reduces 
collagen deposition and αSMA (SMA, 
smooth muscle actin) expression, but induces 
antifibrotic PparG (PPAR, peroxisome 
proliferator- activated receptor) expression.
 ► TgfB2- specific AONs reduce CD45- positive 
immune cell infiltration in MDR2- KO mouse 
livers.
 ► In patients suffering from primary sclerosing 
cholangitis (PSC) and primary biliary cholangitis 
(PBC), rare non- curable CLDs, TGF-β2 levels 
are elevated and correlate with CD45- positive 
immune cell infiltration.
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Box 2 Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► Our data directly suggest the use of TGF-β2 silencing in PSC 
and PBC patients to ameliorate or reverse fibrogenesis.
 ► Given the general safety of TGFB2/TgfB2- specific AONs for 
patients (currently phase 1 clinical trial for glaucoma), a 
clinical trial for fibrotic PSC and PBC patients seems feasible 
in the near future based on our data.
patients progress to liver failure,3 4 while PSC patients exhibit 
a 10%–15% lifetime risk to develop cholangiocarcinoma 
(CCA).5 6 Besides liver transplantation, curative treatment is not 
possible so far for both diseases. Hence, lifelong treatment with 
ursodeoxycholic acid (UDCA) is the gold standard to achieve 
normalisation of liver serum parameters such as alkaline phos-
phatase and gamma glutamyltransferase and to minimise disease 
symptoms such as pruritus and hyperbilirubinaemia.7 Although 
potential to slow down progression to cirrhosis is discussed, 
fibrotic rearrangements are not improved from such treatment. 
Together, this highlights the need for the development of new 
treatment options in the management of PSC and PBC.
In mammals, three different isoforms of TGF-β are described 
(TGF-β1, TGF-β2 and TGF-β3; transforming growth factor beta) 
to regulate apoptosis, proliferation, differentiation, migration and 
invasion processes utilising overlapping but not redundant mech-
anisms. All three isoforms are expressed in the liver, but their 
expression is differentially distributed among liver cell types.8 
TGF-β1 has been extensively studied in healthy and chronically 
injured liver and is proposed as treatment target in multiple clinical 
studies.9
TGF-β2 expression in different liver cell types was described 
nearly 30 years ago,10 11 and was also associated with develop-
mental defects and fibrotic diseases in mice.12–14 In human chronic 
liver diseases (CLDs), few details are known about its functions. 
TGF-β2 was shown to correlate with bad prognosis in intrahepatic 
CCAs and hepatocellular carcinoma.15–18 Mechanistically, canon-
ical Smad signalling as well as crosstalk with Yap, Hippo, Wnt and 
β-catenin signalling have been demonstrated in the liver and other 
organs.19–24 Recently, we have shown that TGF-β2 expression is 
significantly dysregulated during progression of CLDs.25 While 
expression dynamics were mostly similar, a special impact of 
TGF-β2 in biliary- derived CLDs was obvious. Here, the regulation 
of TGF-β1 and TGF-β2 differed pronouncedly, suggesting TGF-β2 
as a promising target to specifically tackle biliary CLDs, such as 
PSC or PBC. The multidrug resistance gene 2 knockout (MDR2- 
KO) mouse model reliably mimicks features of human cholestatic 
liver disease. Knockout of the multidrug resistance gene 2 (Mdr2) 
in mice leads to the absence of biliary phospholipids and the accu-
mulation of toxic bile acids resulting in cholestatic liver injury. This 
injury is accompanied by chronic portal inflammation as well as 
intrahepatic and extrahepatic fibrosis of bile ducts, finally leading 
to biliary cirrhosis and cancer.26
Despite many unsolved questions, such as specificity and transla-
tion into the clinics, interest in antisense oligonucleotides (AONs) 
as small compounds with therapeutic potential is still eminent. 
Major advantages are their easy design, low production costs and 
the possibility to target nearly any cellular process or ‘gene’ wanted.
In this report, we assessed TGFB2 expression in PSC and PBC 
patients and determined the potential of TgfB2 silencing to atten-
uate or inhibit fibrogenesis in cholestatic MDR2- KO mice using 
specific AONs. Taken together, our data indicate that silencing 
TgfB2 in non- parenchymal cells (NPC) attenuates fibrogenic and 
inflammatory responses in MDR2- KO mouse livers and thus 
provides therapeutic potential against inflamed cholestatic liver 
fibrosis with increased TGF-β2 levels.
MATeRIAlS AnD MeTHODS
Human patient samples
The investigation was conducted in accordance with ethical 
standards, with the Declaration of Helsinki and according to 
national and international guidelines.
AOn treatment of MDR2-KO mice (cholestatic fibrosis model)
MDR2- KO mice were kindly provided by F. Lammert 
(Homburg),27 and were maintained in a specific pathogen- free 
environment. The experiments were performed with gender- 
matched mice at the age of 14 weeks. Of note, 50% male and 
50% female mice were used for each experimental setup. Geno-
typing was done as described elsewhere.28 In the first week, all 
animals received either 15 mg/kg29 body weight scramble control 
oligo C3_0047 (Co) or ISTH0047 (AON) each day for 5 days 
(oligo push). The subsequent treatment was applied once per 
week for 3 further weeks. Six groups of animals were defined: 
(1) Balb/c untreated for 4 weeks (n=6), (2) Balb/c control oligo 
(n=10, received 15 mg/kg body weight of Co); (3) Balb/c AON 
(n=10, received 15 mg/kg body weight of AON); (4) MDR2- KO 
untreated (n=10, untreated for 4 weeks); (5) MDR2- KO 
control oligo (n=10, received 15 mg/kg body weight of Co) and 
(6) MDR2- KO AON (n=9, received 15 mg/kg body weight of 
AON). Mice were sacrificed 72 hours after the last treatment 
and specimens sampled for further analysis.
Statistical analysis
Error bars indicate SD in cell culture experiments. For evalua-
tion of mouse and patient data, error bars indicate SEM. Two- 
tailed Student- t tests or one- way analysis of variance were used 
to calculate the p- values. Differences were considered to be 
significant if the calculated p- value was *p≤0.05, **p≤0.01, 
***p≤0.001, ****p≤0.0001; p- values were not significant if 
not indicated or assigned ns. Significance of differences between 
Balb/c and MDR2- KO was only calculated for untreated animals. 
Additionally, Pearson correlation or Fisher’s exact test for clini-
copathological data were performed.
Additional methodology is provided as online supplemental 
information.
ReSulTS
TGFB2 is upregulated in the liver of PSC and PBC patients
TgfB2 is predominantly upregulated in biliary- derived CLDs in 
mice,25 but less in other etiologies (online supplementary figure 
1). We investigated TGFB2 mRNA expression in human liver 
tissue samples of PSC and PBC patients, and liver diseases of other 
etiologies. While TGFB2 was not deregulated in four out of five 
non- alcoholic fatty liver disease (NAFLD) patient cohorts (online 
supplementary figure 2), we confirmed upregulation of TGFB2 
in biliary- derived liver damage in three PSC and PBC patient 
cohorts (figure 1A, p=0.0013; figure 1B, p=0.007; figure 1C, 
pPSC=0.0065 and pPBC=0.0084) and one cohort with intrahepatic 
cholestasis and biliary atresia patients (figure 1D, p=1,79e-07) 
compared with normal liver controls; online supplementary figure 
3 shows a separate graphical presentation of PSC and PBC patients 
from the Regensburg cohort and GSE61260. Thus, our data point 
towards significant TGFB2 upregulation, especially in PSC.
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Figure 1 Patient resolved expression of TGFB2 in tissue of cholestatic liver disease patients compared with healthy individuals. Expression changes 
of TGFB2 in liver tissue of individual patients represented as single dots in (A) the PSC/PBC cohort from Regensburg, (B) the collective GSE61260, 
(C) the PBC and PSC cohort from Poland, (D) the cohort GSE46960 and (E) in low- risk and high- risk patients described in GSE79850 as determined 
in comparison to non- diseased control livers. In (E), low- risk patients responded fully to UDCA treatment. High risk was assigned to the need of liver 
transplantation in the course of disease. Grey dots: PBC; black dots: PSC; **p≤0.01; ***p≤0.001; ****p≤0.0001; NL, normal liver; PBC, primary 
biliary cholangitis; PSC, primary sclerosing cholangitis; TGFB, transforming growth factor beta; UDCA, ursodeoxycholic acid.
Interestingly, TGFB2 expression displayed a significant correla-
tion with the inflammatory grade in the patient cohort from 
Regensburg (online supplementary table 1, p=0.045). From the 
GSE61260 cohort, no such clinical data were available to confirm 
this correlation. TGFB2 was also remarkably upregulated in a 
cohort of nine ‘high risk’ PBC patients who eventually needed 
liver transplantation as compared with seven ‘low risk’ patients, 
who responded to UDCA treatment (GSE79850) (figure 1E, phigh 
vs co=0.0046, phigh vs low=0.0026, online supplementary tables 2 and 
3). These data suggest a predictive ability of TGFB2 expression 
regarding patients’ treatment response. In GSE79850, high TGFB2 
was also significantly associated with higher Scheuer grades (III and 
IV; p=0.0047), which might explain the worse treatment response 
of these patients compared with the patients of milder disease 
stages (online supplementary table 4). High TGFB2 expression was 
also associated with the diagnosis of ductopenia (p=0.0256), but 
not with the inflammation grade in this cohort.
As TGFB2 was also upregulated in liver tissue of alcoholic 
hepatitis patients (online supplementary figure 2), we conclude 
that TGFB2 plays a predominant, but not exclusive role in biliary 
liver disease, and may also contribute to other liver diseases, for 
example, in an inflammatory context.
TgfB2/TGFB2 is localied in areas of ductular reaction and 
fibrotic rearrangement
In situ hybridisation of TgfB2/TGFB2 revealed localisation near 
portal tracts and in areas of fibrogenic rearrangements in PSC 
and PBC patients, as well as in MDR2- KO mice (figure 2A,B). 
This is in line with former work describing TgfB2/TGFB2 
expression in cirrhosis of undefined origin predominantly in 
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Figure 2 Localisation of TgfB2/TGFB2 in human and murine liver tissue and TGF-β2 treatment of primary mouse HSCs as well as mouse and human 
cholangiocyte cell lines. In situ hybridisation was performed to assess TGFB2/TgfB2 localisation in (A) healthy liver tissue and PSC/PBC patients as 
well as (B) wild- type and MDR2- KO mice. In PSC and PBC patients as well as MDR2- KO mice, TGFB2 was localised in portal tracts (green arrow heads) 
and fibrotic rearranged tissue areas. Additional staining was detected in sinusoids (red arrow heads) of the patients’ tissue. Lower panels represent 
enlarged images of boxed areas in the upper panel. Scale bars indicate 200 µm. Expression of fibrotic marker genes was induced in (C) murine 603B, 
(D) human MMNK1 cells and (E) primary mouse hepatic stellate cells on treatment with TGF-β2. Fold expression is given as referred to the correlating 
untreated control of each time point. Error bars indicate SD. *p≤0.05;**p≤0.01. Acta2, actin alpha 2 or alpha smooth muscle actin; Col1a1, collagen 
type I alpha 1; HSC, hepatic stellate cells; MDR2- KO, multidrug resistance gene 2 knockout; NL, normal liver; PBC, primary biliary cirrhosis; PdgfrB, 
platelet- derived growth factor receptor beta; PSC, primary sclerosing cholangitis; TGFB, transforming growth factor beta; TIMP, tissue inhibitor of 
metalloproteinase.
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Figure 3 Study design and AON- mediated TgfB2 downregulation. 
(A) Schedule of animal treatment with control or TgfB2- specific AONs. 
TgfB2 expression was significantly downregulated in Balb/c and 
MDR2- KO animals treated with AONs as (B) analysed by qPCR and (C) 
visualised by in situ hybridisation. *p≤0.05, ***p≤0.001. Scale bars 
indicate 200 µm. AON, antisense oligonucleotides; MDR2- KO, multidrug 
resistance gene 2 knockout; TGFB, transforming growth factor beta.
biliary epithelial cells.10 In agreement, treatment of murine or 
human cholangiocyte cell lines 603B and MMNK1 with TGF-β2 
results in upregulation of fibrogenic marker genes. In 603B 
cells, Acta2 (alpha smooth muscle actin gene), Col1A1 (collagen 
type I alpha 1), fibronectin and PdgfrB (platelet- derived growth 
factor receptor beta) were induced as compared with untreated 
controls (figure 2C). In MMNK1 cells, TGFB1 was significantly 
induced after 6 hours treatment, while TIMP1 (tissue inhibitor of 
metalloproteinases) was induced after 1 hour, but reduced there-
after (figure 2D). In MMNK1 cells, some of the targets show a 
very fast response already after 5 min, suggesting an immediate 
early and direct response probably to a Smad- dependent signal. 
ACTA2, COL1A1 and PDGFRB are as well induced transiently, 
but not significantly.
As a secretory cytokine, TGF-β2 also acts on other liver cell 
types. Accordingly, we demonstrate induction of fibrogenic 
genes in HSCs (figure 2E). Together, these data demonstrate 
profibrogenic activity of TGF-β2 in the liver, including the 
biliary compartment.
TgfB2-specific AOns target liver tissue without adverse 
effects on liver parameters
Driven by these findings and the lack of sufficient treatment 
options for PSC and PBC patients, we aimed to analyse the effect 
of TgfB2 silencing on CLD parameters in MDR2- KO mice on 
treatment with TgfB2- specific AONs. These were engineered as 
17- mer full phosphorothioate LNA- modified antisense oligode-
oxynucleotides ‘4+4’ gapmers (primary sequence in online 
supplementary figure 4). As published by Huber- Ruano et al,30 
after subcutaneous (s.c.) injection, the AONs rapidly translocate 
from the blood circulation predominantly to livers (37.52% of 
total signal) and kidneys (38.06% of total signal) of wild- type 
mice where they are stably present for 2 weeks.
TgfB2-specific AOns downregulate TgfB2 expression in 
healthy and diseased liver
Based on drug delivery and safety testing data, we s.c. applied 
the AON or Co at a dose of 15 mg/kg body weight,29 30 to 14 
weeks old MDR2- KO mice according to the protocol depicted in 
figure 3A. In untreated MDR2- KO mice, TgfB2 expression was 
markedly elevated as compared with wild- type animals (~8.7 
fold). On AON treatment, significant downregulation of TgfB2 
expression was observed in Balb/c wild- type control animals (5.2 
fold) as well as in MDR2- KO animals (12.5- fold) (figure 3B) with 
no negative impact on liver parameters or body weight in both 
strains (online supplementary figure 5A, B). Remarkably, AON 
treatment reduced TgfB2 levels in MDR2- KO mice to normal as 
seen in healthy Balb/c. Upon AON treatment, reduced staining 
of TgfB2 in MDR2- KO mouse tissue compared with untreated 
controls was also visualised by in situ hybridisation (figure 3C).
TgfB2-directed AOns accumulate in nPC
We were interested to identify the target cell type(s) of the AONs 
in the liver. Immunohistochemical staining of Dig- labelled 
AONs revealed that they did not localise to hepatocytes or chol-
angiocytes after s.c. application, but rather accumulated in NPCs 
located in the space of Disse (online supplementary figure 6A). 
Using coimmunofluorescence analysis of labelled AONs and 
marker proteins of different liver cell types, the oligos colocal-
ised with αSMA (SMA, smooth muscle actin), CD31, elastin 
and S100A4 (FSP1) in MDR2- KO liver tissue, indicating uptake 
into activated HSCs, liver sinusoidal endothelial cells (LSECs), 
portal fibroblasts and to a lower extent into macrophages 
(online supplementary figure 6B, colocalisation indicated by 
white arrows). Interestingly, in wild- type mice, AONs colocal-
ised with CD31 positive LSECs only for so far unknown reasons. 
Confirming data from more than 20 years ago, showing TgfB2 
mainly in activated biliary epithelial cells, but also in Kupffer 
cells and other liver cell types in rat and human tissue,8 10 11 
we demonstrate by cell isolation TgfB2 expression in the non- 
parenchymal liver cell fractions HSCs, LSECs and Kupffer cells 
of Balb/c and MDR2- KO mice (online supplementary figure 6C). 
We conclude that AON- mediated TgfB2- downregulation in the 
liver occurs predominantly in NPCs and not in cholangiocytes.
TgfB2-specific AOns decrease ductular reaction and biliary 
damage markers
MDR2- KO mice exhibit periductular onion- skin fibrosis 
and pronounced ductular reactions (DR).31 AON treatment 
improved biliary damage and reduced DR as demonstrated by 
significantly downregulated Muc1 (Mucin 1) mRNA expression 
levels and reduced CK19 (cytokeratin 19), Sox9 (SRY- box 9), 
panCK and Epcam (epithelial cell adhesion molecule) staining of 
the liver tissue (figure 4A–E).
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Figure 4 TgfB2- silencing by AONs reduced biliary damage and ductular reactions (DR). Immunohistochemical staining of (A) CK19, (B) Sox9, (C) 
and panCK, as well as (D) immunofluorescence- based detection of Epcam as a markers of DR and (E) qPCR of Muc1 as a marker of biliary damage 
revealed significant downregulation in AON- treated MDR2- KO mice. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001; scale bars indicate 50 µm for 
CK19, and 100 µm for Sox9, panCK and Epcam. AON, antisense oligonucleotides; MDR2- KO, multidrug resistance gene 2 knockout; Muc, Mucin; TGFB, 
transforming growth factor beta.
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TgfB2-specific AOns decreased hydroxyproline content, 
collagen deposition and αSMA expression in MDR2-KO mouse 
livers
In line with data demonstrating that DR correlates with fibrosis 
in experimental models of liver disease,32 we next analysed the 
consequences of TGF-β2 downregulation on liver fibrogenesis. 
In MDR2- KO mice, hydroxyproline content, collagen deposi-
tion and αSMA expression were elevated compared with Balb/c 
controls. AON treatment significantly decreased hydroxypro-
line content and Sirius Red stained areas of liver tissue (~56%) 
compared with untreated MDR2- KO mice (figure 5A,B). Further, 
periductular αSMA staining was significantly reduced (~35%) 
on AON- treatment in MDR2- KO mice, which was confirmed by 
immunoblot (figure 5C,D). Hydroxyproline did not change in 
wild- type Balb/c mice on AON treatment and rather no collagen 
deposition or αSMA was present.
These data suggest for the first time an antifibrotic effect of 
TgfB2- directed AON treatment in liver.
TgfB2-directed AOns elevate PparG and chemokine 
expression in MDR2-KO mouse livers
We next examined fibrosis marker expression. In contrast to 
TgfB2, TgfB1 was not induced in MDR2- KO compared with wild- 
type mice,25 underlining the predominant role of TGF-β2 in this 
model. AON treatment did not change TgfB1 and Ctgf (connec-
tive tissue growth factor) expression (figure 6A). In MDR2- KO 
animals, Timp1 expression was increased as published before,33 
but AON treatment showed no reducing effect (figure 6A). 
Expression of PparG (inversely associated with fibrosis and 
inflammation before34 35) was significantly induced by AON- 
treatment in MDR2- KO mice, supporting an antifibrotic effect 
of TgfB2 silencing (figure 6B). TGF-β2 treatment reduced PparG 
expression in mouse JS-1 cells and primary mouse HSCs (online 
supplementary figure 7, figure 6B) underlining the profibrotic 
capacity of TGF-β2.
Since we did not find significant AON effects on genes usually 
altered in fibrosis despite improvement of collagen deposition 
and αSMA expression, we attempted to get a broader insight 
on AON- dependent gene expression changes and performed 
a fluidigm- based real- time PCR analysis of selected fibrosis 
and inflammation associated genes (see online supplemen-
tary table 6). AON- treatment of MDR2- KO mice upregulated 
Mki67, Notch3, Ccl3 (C- C motif chemokine ligand), Ccl4 and 
Ccl5 in liver tissue compared with untreated and oligo- treated 
MDR2- KO mice (figure 6. online supplementary table 5). 
Except for Notch3, the AON effect was also present in Balb/c 
mice, suggesting a context- independent influence of the AON 
on TGF-β2 target genes.
These data argue for increased (compensatory) proliferation 
and modulated immune response in AON- treated mice; an AON- 
dependent increase in number of Ki67- positive nuclei as shown 
by immunohistochemistry, especially in hepatocytes, as well as 
PCNA induction as demonstrated by immunoblot confirmed this 
outcome (figure 6D,E).
We also report an off- target C3-0047 control oligonucleotide 
effect.36 In MDR2- KO mice, but not Balb/c mice, the control 
oligo caused downregulation of the chemokine receptors Ccr2 
(C- C motif chemokine receptor), Ccr3, Ccr5 and Cxcr1 (C- X- C 
motif chemokine receptor) similar to the specific oligo. Both 
also affected the expression of Ifna1 (interferon alpha), Ifnb1, 
Ch25h, Rps18, Notch1, Il10rb and Mrc1. In this respect, we 
also mention the control oligo- dependent decrease of Sirius red 
staining in MDR2- KO mice (figure 5B).
TgfB2-specific AOns modulates the inflammatory niche of 
MDR2-KO mouse livers
Inflammation contributes to the development of chronic 
cholestatic liver disease.26 Accordingly, F4/80 positive cell 
numbers were increased in MDR2- KO mice (figure 7A, online 
supplementary figure 8A). Interestingly, TgfB2- directed AON- 
treatment further increased the F4/80- positive cell population 
in the tissue within the myeloid compartment (CD3/CD19/
NKp46/DX5negCD11b+). No significant changes in expres-
sion of Il1B (interleukin1 beta), TnfA (tumour necrosis factor 
alpha) and Il6 (M1 phenotype) or Il13, Il4 and Arg1 (arginase 1) 
(M2 phenotype) occurred in MDR2- KO mice after AON treat-
ment (figure 7B,C). FACS analysis revealed an AON- dependent 
enrichment of infiltrating eosinophils (online supplementary 
figure 8B left column) rather than macrophages in five out of 
six mice. Eosinophils express F4/80,37 (online supplementary 
figure 8B middle column), which may explain our findings. The 
remaining myeloid cells in AON- treated mice mainly comprised 
Ly6G lymphocyte antigen 6 complex locus G6D)+neutrophils 
and Ly6C+monocytes, whose numbers did not significantly 
increase on treatment (online supplementary figure 8B right 
column).
We also analysed the inflammatory status of the mice by 
staining the panleukocyte marker CD45 (figure 7D) and found 
a significant decrease of infiltrating inflammatory cells in AON- 
treated MDR2- KO mice. Further analysis of lymphoid cell infil-
trates (online supplementary figure 8C) revealed a significant 
AON- dependent increase in numbers of cytotoxic CD8+ T cells 
(online supplementary figure 8D). Numbers of other lymphoid 
immune cells did not change significantly, although in tendency, 
numbers of CD4+ T cells and Tregs were reduced by AON treat-
ment. These findings in total point towards ameliorated inflam-
mation in the livers of AON- treated MDR2- KO mice.
Which exact cell type can be accounted for the overall down-
regulation of the CD45+ compartment needs further investiga-
tion and is essential to allow detailed mechanistic and functional 
explanation of our finding.
CD45 and TGFB2 expression levels correlate in PSC and pBC 
patients
In PSC and PBC patients, CD45 mRNA is upregulated by trend 
in comparison to normal liver (figure 8A), while no significant 
elevation of PPARG expression was detected (figure 8B). Inter-
estingly, CD45 expression correlated with TGFB2 expression 
in PSC/PBC patients from the Regensburg cohort (figure 8C, 
p=0.0255). Immunohistochemical staining confirmed high 
TGF-β2 expression in liver tissue of patients with high CD45+ 
cell infiltration (figure 8D). In patients with low numbers of 
CD45+ cells, only little TGF-β2 was detected. Thus, patients’ 
data confirmed a possible mechanistic link between the number 
of CD45+ cells and TGFB2/TGF-β2 levels, as shown in mice.
DISCuSSIOn
The TGF-β superfamily has been shown to be a promising field to 
tackle human diseases from fibrosis to oncogenesis by experts of 
all areas including cardiology, nephrology and gastroenterology 
in research and clinics.38 Accordingly, members of the TGF-β 
superfamily are currently analysed in clinical and preclinical 
studies as therapeutic targets for several diseases using different 
approaches of interference.38 Although in some cases, pan- 
TGF-β reagents targeting all three isoforms are applied, meth-
odologies specifically directed towards TGF-β2 are rare. Rabbits 
receiving subconjunctival injections of a TGF-β2- neutralising 
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Figure 5 Impact of AON- mediated TgfB2 silencing on collagen expression and deposition as well as αSMA expression in MDR2- KO mice. (A) 
Hydroxyproline (HYP) content in the liver of AON- treated MDR2- KO mice was significantly downregulated compared with untreated and control 
oligo- treated animals. (B) Sirius red staining (pSR) revealed significant downregulation (~56%) of collagen deposition in the tissue of AON- treated 
compared with untreated MDR2- KO mice. Scale bars indicate 500 µm. (C) Immunohistochemical staining demonstrated a decrease of αSMA 
expression in AON- treated animals of 35% compared with untreated animals and 43% compared with animals treated with control oligos. Scale bars 
indicate 200 µm. (D) Reduction was verified by immunoblot analysis. *p≤0.05, **p≤0.01, ***p≤0.001. AON, antisense oligonucleotides; MDR2- KO, 
multidrug resistance gene 2 knockout; SMA, smooth muscle actin; TGFB, transforming growth factor beta.
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Figure 6 Regulation of fibrosis marker gene expression by TgfB2 silencing. (A) TgfB1, Ctgf and Timp1 mRNA expression was not considerably 
changed by TgfB2- directed AON treatment. (B) Expression of antifibrotic and anti- inflammatory PparG was markedly upregulated by AONs in 
MDR2- KO mice. According to a profibrotic role of TGF-β2, TGF-β2 treatment of primary mHSCs inhibited PparG expression. Error bars represent SD 
for the mHSC experiment. ***p≤0.001. (C) Fluidigm analysis of fibrotic and inflammation- related marker genes (see online supplementary table 
6) revealed specific AON- based effects of TgfB2 downregulation as well as placebo- associated effects of oligo treatment in MDR2- KO mice (also 
see online supplementary table 5) presented as 3D plot. Log2FC values are shown. Changes were considered significant, if Log2FC was >0.5 or 
<−0.5 and one- way analysis of variance plus Tukey analysis revealed p- values<0.05, here shown as *; ns=non- significant. (D) Ki67 expression was 
detected by immunohistochemistry in liver tissue of treated and untreated Balb/c and MDR2- KO mice. Quantification was performed for all cells as 
well as separated for hepatocytes (HC) and non- parenchymal cells (NPC). *p≤0.05, **p≤0.01. Scale bars indicate 200 µm. (E) Immunoblot analysis 
of PCNA expression. AON, antisense oligonucleotides; Ctgf, connective tissue growth factor; MDR2- KO, multidrug resistance gene 2 knockout; PCNA, 
proliferating cell nuclear antigen; Ppar, peroxisome proliferator- activated receptor; TGFB, transforming growth factor beta; Timp, tissue inhibitor of 
metalloproteinases.
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Figure 7 Infiltration of immune cells into the liver tissue of AON- treated MDR2- KO mice compared with controls. An anti- inflammatory role of 
TGF-β2 was suggested. (A) In AON- treated MDR2- KO mice, increased amounts of resident F4/80- positive macrophages were detected. These are 
probably not polarised to typical M1 or M2 phenotypes as levels of (B) TnfA, Il6 and Il1B and (C) Il13, Il4 and Arg1 were not changed by AON 
treatment. (D) Immunohistochemical staining of CD45 revealed significant downregulation in AON- treated MDR2- KO mice. *p≤0.05, **p≤0.01, 
***p≤0.001. Scale bars indicate (A) 50 µm or (D) 200 µm. AON, antisense oligonucleotides; Arg, arginase; Il, interleucin; MDR2- KO, multidrug 
resistance gene 2 knockout; TGFB, transforming growth factor beta; Tnfa, tumour necrosis factor- alpha.
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Figure 8 Analysis of inflammation marker expression with respect to TGFB2 expression in PSC and PBC patients (Regensburg cohort). Expression 
of (A) CD45 and (B) PPARG in liver tissue of PSC and PBC patients was determined. (C) CD45 expression levels correlated with TGFB2 expression 
levels of the same patients (left: Pearson Correlation pTGFB2/CD45=0.0255; rTGFB2/CD45=0.61). (D) Immunohistochemical staining of TGF-β2 and CD45 in 
liver tissue of PSC patients with low (patient 3) and high (patient 4) CD45 levels as well as healthy controls (patient 1, 2=NL). Scale bars indicate 200 
µm for NL, for PSC scale bars indicate 100 µm. NL, normal liver; PBC, primary biliary cirrhosis; PPAR, peroxisome proliferator- activated receptor; PSC, 
primary sclerosing cholangitis; TGFB, transforming growth factor beta.
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antibody (CAT-152) after glaucoma surgery display significantly 
improved outcome, and in accordance with our data in liver, 
present reduced subconjunctival collagen deposition.39 40
Based on results on TGFB2/TgfB2 deregulation in animal 
models of biliary- derived diseases and its profibrogenic effects 
in HSCs and cholangiocytes, we are interested in its potential 
role in PSC and PBC patients also presenting elevated TGF-β2 
levels. To get further insight, we targeted TGF-β2 in early stage 
biliary liver disease of MDR2 knockout mice in order to atten-
uate or reverse disease parameters related to fibrogenesis and 
inflammation.
Clinical trials as well as in vivo studies using AONs delineating 
the function of specific genes have already been reviewed back 
in the 90s of the last century.41 42 Despite remaining obstacles, 
these molecules have been developed into next generations 
including backbone modifications to optimise, for example, 
half- life, cellular uptake and binding affinities and have been 
proven to be valuable tools since then.43–45 Accordingly, AONs 
used in this study were designed to meet these state- of- the- art 
requirements and were subsequently approved to be well toler-
ated with respect to well- being and liver parameters in mice and 
to selectively downregulate TgfB2 in the livers. Our data argue 
for increased AON uptake into activated NPC such as fibroblasts 
and macrophages in damaged livers as compared with quiescent 
cell populations in healthy livers, where AONs predominantly 
target LSECs. To this state, we cannot explain the mechanistic 
background and the physiological meaning of this finding. 
Control oligo- associated deregulation of chemokine receptors 
and few other genes (placebo effect) in MDR2- KO but not in 
Balb/c mice could for example be due to different uptake modal-
ities in wild- type versus disease- activated liver cells.
Tumour growth reducing effects of TgfB2- targeting AONs 
were reported in malignant mesotheliomas,46 highlighting 
TGF-β2 as a druggable target. In animal models, fibrotic diseases 
have been successfully tackled using AONs against TGF-β signal-
ling components and other fibrogenic drivers in the past. For 
example, Timp2 downregulation by AONs ameliorated fibro-
genesis in rats and in line with our model reported here, signifi-
cantly reduced collagen deposition, while in contrast to us, HSC 
activation (αSMA expression) remained unchanged.47 Likewise, 
Uchio et al48 described mild preventive effects of TgfB1 and 
Ctgf- directed AON treatment in CCl4- induced liver fibrosis as 
measured by procollagen mRNA expression.
Smad7, endogenous inhibitor of TGF-β, was also successfully 
targeted by AONs in different diseases. Oral administration of 
Smad7- directed AONs ameliorated colitis in mice which pres-
ents with high TGF-β1 levels but defective signalling due to 
high SMAD7 levels.49 Further, higher remission rates and clin-
ical responses were shown in Crohn’s disease patients receiving 
Smad7- specific AONs.50
Our data demonstrate attenuation of fibrogenesis in 
MDR2- KO mice by silencing TgfB2 accompanied by significant 
downregulation of CD45- postive cell infiltration and upregula-
tion of at least one anti- inflammatory component (PparG). A link 
between TGF-β2 function and inflammation has been described 
before for different organs and pathologies. However, here it 
is discussed for the first time in the context of liver fibrosis. 
Maleszewska et al described that costimulation of human umbil-
ical vein endothelial cell cells with IL-1β and TGF-β2 resulted 
in EndMT (endothelial to mesenchymal transition) mediated by 
upregulation of inflammatory NFκB signalling.51 In liver, our 
data also suggest proinflammatory effects of TGF-β2; if silenced, 
reduction of inflammatory cells occurred which probably subse-
quently attenuated fibrosis. Opposing our data, TGF-β2 inhibits 
LPS- induced cytokine production of macrophages in intestinal 
tissue characterising the cytokine as an anti- inflammatory factor 
in this organ.52
Just recently, TgfB2 silencing in mice using the same AONs 
avoided lung metastasis induced by kidney, breast and lung tumor- 
derived cell lines.30 It is concluded that this in part would be due 
to induction of CD86 expression in tumour associated macro-
phages, influencing the immunological niche. Here, we also found 
a prominent modulatory effect of TgfB2 (silencing) on the complex 
fibrotic and immunological fate in MDR2- KO mouse livers.
It seems obvious, that TGF-β2 as other regulatory cytokines 
has multiple cell- type as well as context- dependent and inflam-
mation modulatory roles. Thus, it remains to be explored for 
any tissue, cell type and disease stage whether TGF-β2 has 
beneficial or adverse effects on disease development or progres-
sion. Our data indicate that downregulation of inflammatory 
cell infiltrations by TgfB2- targeting AONs in inflammation- 
associated biliary fibrosis is of advantage for the diseased animal. 
Further, TgfB2- silencing modulated F4/80- positive cell numbers. 
F4/80- positive macrophages can be activated to an M1 pheno-
type associated with an increased secretion of inflammatory 
cytokines such as Il1β, Tnfα and Il6,53 or can be polarised to 
an M2 status with, for example, Il13, Il4 or Arg1 expression 
taking part in Th2 responses such as inflammation dampening 
and tissue remodelling.53–55 We could not find any regulation of 
these markers from AON treatment, indicating that liver resi-
dent macrophages rather present with mixed and subsequently 
context- dependent specialised phenotypes instead of expressing 
exclusive M1 or M2 marker profiles.56–58 To get detailed insight, 
a thorough characterisation of the F4/80 positive population 
in MDR2- KO animals before and after AON treatment could 
be performed taking into account findings of Guicciardi et al 
published in May 2018.59 Interestingly, our analysis suggests 
that within the F4/80+ myeloid compartment rather eosinophils 
than liver resident macrophages are affected by AON treatment. 
Eosinophils express CCR3 and based on our data, we suggest 
that AON treatment may recruit eosinophils via CCR3 by 
inducing CCL5 expression in the liver tissue. Eosinophils may 
support liver regeneration,60 which is in accordance with our 
data showing PCNA and Ki67 upregulation and PparG down-
regulation on AON treatment.61 We conclude that improved, 
regenerative processes contribute to the beneficial AON effects 
in MDR2- KO mice.
When analysing the lymphoid compartment, we demonstrated 
increased numbers of CD8+ T cells as well as lower numbers of 
CD4+ T cells and Tregs by trend. The latter two together may 
account for overall significant reduction of CD45+ cell infiltra-
tion which is in line with less CD45- positive staining in healthy 
human liver tissue and patients with low TGF-β2 levels. According 
to current knowledge, TGF-β1 is involved in generation/matura-
tion of Tregs and Th17 cell populations. The decrease in Tregs on 
AON treatment would be in line with a potentially similar func-
tion of TGF-β2. How this integrates in detail in the disease- related 
inflammatory, NPC and parenchymal cell communication,62 
and accounts for the net effect on disease parameters warrants 
further investigations. The specific role of Tregs and Th17 cells 
is still controversially debated in the field of autoimmune hepa-
titis, including in PSC and PBC.63 We can speculate that in line 
with a recent study, Tregs, instead of being anti- inflammatory, may 
suppress NK cells (M1) Kupffer cells and CD8+ T cells, but not 
CD4+ cells in fibrotic mouse liver, there being also able to promote 
a proinflammatory microenvironment and enhance fibrogenesis.64 
Antifibrotic effects of TGF-β2- directed AONs could be explained 
by reduced Treg infiltration rates providing an anti- inflammatory 
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niche. However, final conclusions are difficult to draw at this point 
and further studies are warranted.
Of note, no gender differences for AON specificity and effec-
tiveness were detected in our mouse model with respect to TgfB2 
expression as well as CD45 and αSMA staining quantification 
(data not shown).
To our knowledge for the first time, we demonstrate bene-
ficial effects of TgfB2 silencing in the development of rodent 
liver fibrosis. Safe application, tolerability and antifibrotic and 
immune- modulatory effects of TgfB2- directed AONs in a biliary- 
derived fibrosis model, as well as the upregulated TGFB2 levels 
in PSC or PBC patients suggest testing AON efficacy in the treat-
ment of patients with biliary cholestatic fibrosis, especially if 
associated with increased CD45+ cell infiltration. As no healing 
treatment for these rare but detrimental diseases are available 
yet, clinical trials targeting TGF-β2 would possibly offer positive 
prospect for the patients.
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